Servier Interviews Stage 4 Cholangiocarcinoma Survivor Steve Holmes
Steve Holmes on survival, his brother Graeme's cholangio battle, founding the Cholangiocarcinoma Foundation Australia and Light Australia Green
Leading the Future of Cholangiocarcinoma Care—Because No One Else Will
Landmark Event: Leading experts & patient advocates united for the largest-ever event on cholangiocarcinoma treatment standardisation in Australia, driving innovation & action.
Catie Brown
Malua Bay mum Jill Brown’s mission to educate Australia on rare cancer that killed ‘beautiful’ daughter Catie. Jill Brown tragically lost her “beautiful” daughter Catie Brown in early 2023, after a hard fought six month battle with cholangiocarcinoma, a rare bile duct cancer.
Understanding Bilirubin: Your Body’s Natural Blood Compost
Learn about bilirubin, its role in your body, symptoms like jaundice and itching, and how to track and respond to changes that impact liver and bile health.
TAS-120: Futibatinib in Advanced Cholangiocarcinoma with FGFR2 Fusions
TAS-120 (Futibatinib) offers hope for advanced cholangiocarcinoma with FGFR2 fusions. Explore the groundbreaking FOENIX-CCA4 Phase 2 study results.
Orphan Drug for Intrahepatic Bile Duct Cancer
Discover how PLT012, an innovative anti-CD36 antibody, targets liver cancer's sneaky recruitment stations, starving tumours, dismantling defences, and empowering T-cells to attack.
World-First Pilot Study Explores New Cholangiocarcinoma Treatment
Join a world-first pilot study testing durvalumab and olaparib for advanced cholangiocarcinoma. Now recruiting at eight sites across Australia. Learn more.
Lynette Williams cholangiocarcinoma survivor
Lynette Williams’ journey from diagnosis to survival highlights the impact of knowledge, advocacy, and expert care in beating cholangiocarcinoma.
Immunotherapy and Chemotherapy Combinations for Cholangiocarcinoma
FDA approves Keytruda combo for cholangiocarcinoma, expanding options alongside Durvalumab. Explore immunotherapy breakthroughs and chemo combinations.
Jon’s Five-Year Cholangiocarcinoma Journey
Jon’s journey with cholangiocarcinoma is a testament to resilience and determination. Nearing her five-year milestone, she shares the strength that has kept her fighting.
The Luckiest Unlucky Guy – The Matt Reidy Story
Matt's story shines a light on overcoming cholangiocarcinoma, from diagnosis and treatment to becoming a beacon of hope in the cancer community.
Evaluating the New Cholangiocarcinoma Vaccine Trial: A Patient-Centric Analysis”
An in-depth analysis of a cholangiocarcinoma vaccine trial, designed to empower patients with balanced insights into this experimental treatment.
Fixing Broken IDH1 in Cholangiocarcinoma: How Inhibitors Are Changing the Fight
Discover how blocking broken IDH1 with inhibitors is helping cholangiocarcinoma patients. Cholangiocarcinoma Foundation Australia is helping better equip and empower patients to respond more effectively.
IDH1-Mutated Cholangiocarcinoma: Understanding PARP Inhibitors and Clinical Trials
Explore the latest research and clinical trials involving PARP inhibitors for treating IDH1-mutated intrahepatic cholangiocarcinoma.
Michael Flannery: Life Goes On: My Journey with Cholangiocarcinoma
Michael’s Journey: Overcoming Cholangiocarcinoma with Resilience, creative persistence, Hope, and Action gave him back a normal life
Steve Holmes Patient Survivor: 14000 kilometre Cycling Circumnavigation of Australia
Cycling to Empower patients. Transform survival outcomes. Support our innovative cancer response strategies and make a real difference today.
The Checkpoint Pathway: Ipilimumab and Keytruda immunotherapy combination
Discover how the combination of Ipilimumab and Keytruda removes the brakes and disguises cancer cells use to evade the immune system, offering new hope through immunotherapy.
Understanding BRCA1 and BRCA2 in Cholangiocarcinoma
Discover how BRCA1, BRCA2, and BAP1 genes influence cholangiocarcinoma and why understanding them is crucial for effective treatment.
Bile Gone Bad-Article 3: Understanding Bile Duct Damage and Bile Duct Cancers
Uncover the hidden link between poor bile composition and the alarming rise in bile duct cancer rates.
Meet GEM/CIS/DURVA: A Formidable Trio in the Fight Against Cancer
Discover how GEM/CIS/DURVA works to fight cholangiocarcinoma more effectively
Silent Chronic Inflammation and Rising Cholangiocarcinoma, Especially in Younger Patients
Investigate the role of poor bile composition in the increasing rates of bile duct, liver, and pancreatic cancers.
Bile Gone Bad: The Rising Incidence of Bile Duct Cancer – The Hidden Dangers within Bile Composition
Is your diet turning your bile toxic? Learn about the hidden cancer risks and how to protect your health.
Unlocking the Power of Immunotherapy and Gem/Cis: A Strategic Battle Plan for Fighting Cholangiocarcinoma
Discover the powerful synergy of immunotherapy and Gem/Cis in fighting cholangiocarcinoma and empowering patient survival. Discover the powerful synergy of immunotherapy and Gem/Cis in fighting cholangiocarcinoma and empowering patient survival.
Meet Olaparib: A Key Player in the Fight Against Cancer
Discover how Olaparib, a breakthrough PARP inhibitor, enhances cancer treatment for patients with BRCA mutations. Learn more about its benefits and uses.
Defeating Biliary Tract Cancer with ARTEMIDE-Biliary01: A New Hope
Uncover how ARTEMIDE-Biliary01 could revolutionize biliary tract cancer treatment with innovative adjuvant therapy.
AMG193 Trial targets MTAP Loss
Just Imagine a big school where every student (cell) has a special recycling bin called MTAP but for some reason they disappear or the lid wont open the rubbish piles up and...
Brenda’s Testimonial
It's been an absolute whirlwind as she was dying in my arms 2 weeks ago and the Drs didn't want to treat her - now we have this option, thankyou!
James Hastings Testimonial
Hope you guys made it home and sound, just read the patient journal cover to cover, (on my flight to UCL for next round of Nivo) it's incredible,.the detail, the path it forges, the ideas and inspiration. Truly amazing and exactly what is needed to navigate CCA, Brilliant James Hastings - Ireland
AstraZeneca’s Imfinzi breaks decade Long Drought in Cholangiocarcinoma
IMFINZI® will serve as a first-line treatment for locally advanced or metastatic cholangiocarcinoma in combination with chemotherapy (Gem/Cis).
Transforming Cancer Perceptions: The Power of Objectivity
Putting Cancer in Its Rightful Place — A Journey Toward Empowered Patienthood
Exploring HIPEC Surgery: A Potential Ally in Abdominal Cancer Battles
Discover HIPEC Surgery, an innovative treatment for abdominal cancers. Learn how it works, its benefits, and who can benefit from it.
Clarifying: What is the Checkpoint Pathway?
It is the Successful Handshake that that Occurs between 'PD-1' - the T-Cells Checkpoint Police Officer and 'PD-L1' The Healthy Cells Good Citizen Pass.
The Basics difference between Gem/Cis with Durvalumab vs. Keytruda
Explore the differences in cancer treatments using Gem/Cis with Durvalumab versus Keytruda, focusing on innovative immunotherapy strategies for patient empowerment.
Merck’s Keytruda: A New Hope in Biliary Tract Cancer
Merck's Keytruda gains FDA approval for biliary tract cancer, promising extended survival, rivaling AstraZeneca’s Imfinzi.
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
PBAC endorses IMFINZI (durvalumab) for advanced biliary tract cancer in Australia. First new treatment in 10+ years, boosting survival rates.
Testimonials
CCF Australia is a professional 'Patient-Centric' and 'Patient-Led' Organisation, [...]
Steven West: Cholangio Survivor
The opportunity to help other newly diagnosed patients help themselves, to understand in a manner that they can mount a robust and effective response is the reward
Lynette Williams: Cholangiocarcinoma Survivor
In order to successfully fight this disease we need to be armed with as much information as possible.
Lisa Salem-Craine: Cholangio Survivor
I met Steve and Claire Holmes many years ago and connected with them because like Steve, I am a cholangiocarcinoma survivor.
Lisa Craine
Beating Cholangiocarcinoma, a bile duct cancer. After several resections and lot of determined research Lisa prevailed
Melinda Bachini
Surviving Cholangiocarcinoma a bile duct cancer is a significant challenge within the cancer world. Melinda Bachini took it on with an amazing supporter community underpinned by willingness and persistence.
Second Opinions Save lives
Second Opinions are a critical factor in surviving Cholangiocarcinoma a bile duct cancer, it an mean the difference between life and death
Andrea Sheardown
Taking on challenges creates a positive environment and positive is what works for Andrea
Intrahepatic Cholangiocarcinoma – Diagnosis and Treatment
Fralin Biomedical Research Institute Timothy Pawlik, M.D., Ph.D. dives deep into discovering and treating intrahepatic cholangiocarcinoma
World Cholangiocarcinoma Day
Contribution and Sharing are powerful human elements in the cancer cure equation - this is my contribution.
Treat the Immune not the Cancer
A breakthrough by Dr Jim Allison Nobel Prize winner - we look into the Ipi /Nivo treatment, a two pronged attack on reactivating the T-Cell
What are Biomarkers
Biomarkers may be used to better understand some of the characteristics of your cancer. Getting tested for biomarkers helps your doctor decide what options are right for you.
PD-1 / PD-L1 is the Checkpoint Pathway
Learn how simple the PD-1 / PD-L1 Pathway is to understand - 4 short videos from easy to technical
A future look into Immuno-Oncology
what a line up! 2018 Nobel Prize winner James P. Allison, Philip D. Greenberg, M.D and Robert H. Vonderheide, Ph.D., and a fireside chat featured insights and opinions from Bristol-Myers Squibb's Vice President, Head of U.S. Oncology
Blood Biopsies increasing MSI-high detection
A barrier to improved outcomes for many patients is the awareness and testing of MSI status
Ariella Chivil, Cancer Patient success – immunotherapy
Ariella Chivil, an Immunotherapy Advocate, shares her story of self-advocacy and resilience as a young survivor of Hodgkin lymphoma at the 2019 CRI Immunotherapy Summit in Boston.
Cholangiocarcinoma beyond the Blockade
Breakthroughs, Options and Opportunities opening up beyond the Check point inhibitor - beyond PD-1 and the T Cell
Mandy Wallace – NED Cholangiocarcinoma Patient
NED 7.5 years - I woke up on the morning of my 39th birthday with severe pain in my upper abdomen. By lunchtime I had to canceled my birthday party and went to hospital Emergency Department instead. The hospital concluded that I had gallbladder issues, so an ultrasound was scheduled and was sent home with given painkillers to await an ultrasound.
Cholangiocarcinoma and FGFR2
FGF and FGFR2 is a signalling pathway - Fibroblast growth factor signalling uses a fibroblast growth factor receptor (FGFR2) ligand during cell cycle and cell division. The ligand embeds itself into the cell membrane to recieve and deliver growth factors into the cell.
Gem/Cis gets nab-paclitaxel
So, knowing I had no clinical trials for them motivated me to try to write one and think of one that would be something anyone sitting in my clinical could be considered for because that’s what they need.
Scanxiety a new challenge and a special thank you
A Contradiction - It has been what seems like a very long, difficult and unusual battle / journey and with contradictions aside has passed in the blink of an eye.
CCA Patient Toolkit
Step-by-step guide & toolkit for bile-duct cancer patients and caregivers, a road map that shines a light on the best pathway ahead
Cholangiocarcinoma Network
Cholangiocarcinoma Australasia Support Network World Wide - Reaching for a Cure
Immuno 101
An extract collection of material and articles that relate to Cholangiocarcinoma
Susan Randolph Braden’s Can Sir Production
March 2019 has come roaring in like a lion, and like a Mama lioness, I have been aggressively battling my cancer predator this month.
CCA Introduction pack
Cancer breakthrough -The Globally connected patient and caregiver knowledge, experiences and wisdoms - a collective the equips and empowers
Steve and Claire at the 2019 Cholangiocarcinoma Foundation Annual Conference
Steve and Claire at the 2019 Cholangiocarcinoma Foundation Annual Conference [...]
Genomic Testing – Know your mutations
Molecular Testing Know your Mutations , Information is powerful it improves outcomes
MSI Predictive Biomarkers GI
Experts John L. Marshall, MD, and Alan Venook, MD, comment on the evolution of testing for microsatellite instability (MSI) and tumor mutation burden (TMB
Maria
Maria Shearer shares her story with Cholangiocarcinoma and founding The Cholangiocarcinoma Awareness Facebook Group Community. A Caregivers Story with a twist. Maria Shearer has endured and she has made a difference, she stepped out and up to help others.
Dr Charles Drake explains about Exhausted T Cells
Dr Charles Drake explains about Exhausted T Cells in immunotherapies [...]
Michael Lax sought a second opinion
Michael Lax sought a second opinion on Cholangiocarcinoma at UCSF [...]
Melinda Bachini’s Cholangiocarcinoma Patient Perspective
Melinda Bachini's Cholangiocarcinoma Patient Perspective on Adoptive Cell Therapy,
Treatment options improving for Cholangiocarcinoma
Treatment options improving for Cholangiocarcinoma with Kate Kelly encouraging clinicians to perform tumor profiling
The Immuno sliver bullet; is Immunotherapy a “silver bullet” or is it hype?
The Immuno sliver bullet; is Immunotherapy a “silver bullet” or [...]
Bile Ducts made easy – bile ducts, liver, stomach, pancreas, duodenum
Bile Ducts made easy - An easy to follow video on the relationship between the bile ducts, liver, stomach, pancreas, duodenum and more such as Ampular, Hepatic Artery . . .
Chemotherapy and Cholangiocarcinoma
Chemotherapy and Cholangiocarcinoma - The future direction of Chemotherapy in [...]
As a Cholangiocarcinoma patient living in Australia
As a Cholangiocarcinoma patient living [...]
Cholangio Immuno Warrior strikes another blow on “Cholangio the Beast”
Hi everybody! I think its time for an update because I feel so many of you need some hope. More than ever. I have noticed there are fewer positive news in the last months.
Cholangiocarcinoma – Keytruda as a first line treatment option ?
Cholangiocarcinoma - Keytruda as a first line treatment option ? [...]
Treatment of Intrahepatic Cholangiocarcinoma: A Disease on the Rise
Cholangiocarcinoma - Treatment of Intrahepatic Cholangiocarcinoma: A Disease on the [...]
Surgery for Bile Duct Cancer
Surgery for Bile Duct Cancer, There are 2 general types [...]
Investigating the Biliary RFA Procedure
Investigating the Biliary RFA Procedure for Extrahepatic Cholangiocarinoma Information improves [...]
Sarah Bennett & Linda Fleischer
Cholangiocarcinoma Warrior founder Sarah Bennett and her mother Linda Fleischer [...]
Cholangiocarcinoma – About and Options by Mayo Clinic
Cholangiocarcinoma - Sumera H. Rizvi, MBBS. Gastroenterology fellow at Mayo [...]
Katie Barker, University of Utah 2018, Cholangiocarcinoma and Nutrition
Cholangiocarcinoma and Nutrition and Gastro Intestinal Cancers information that needs [...]
Cholangiocarcinoma Treatment lmproving
THE INCIDENCE of cholangiocarcinoma is rising, and effective therapies are [...]
Adrienne Skinner Cholangiocarcinoma and Keytruda
Adrienne Skinner: Living Life to [...]
Keytruda works on Cholangiocarcinoma Patient
Keytruda works on Cholangiocarcinoma Patient. Adrienne Skinner of Larchmont, [...]
Keytruda may be a miracle cancer drug
Keytruda may be a miracle cancer drug but big questions are being asked about affordability to the people who need it most
Vyriad Expands Phase 1 Trial to Test Voyager-V1
Vyriad is expanding its ongoing Phase 1 clinical trial [...]
Rare Cancers Australia 33 Million Win
The Turnbull Government will provide $33 million to our world [...]
Cycling in the Chemo
Cancer hospital getting chemo patients on bikes to [...]
Bile Duct Cancer – How it develops and how to prevent it
Information improves our Outcomes What do you think about [...]
Capecitabine Improves Survival of Patients with Rare Cancer by Almost a Quarter
Information improves our Outcomes What do you think about [...]
CC with Andrew Clacher
“Having a cancer and no one knowing what it is, or what your fate’s going to be, or even if you’re going to be here in the next two years – it really makes you think about your mortality.”
Elishka’s Story
Choliangiocarcinoma: miss Cholangio was diagnosed in Oct 2015, after I had symptoms of menopause, it was already 7cm x 8cm in the liver, and wrapped around all three major blood vessels, so no surgery for me
Immunotherapy achieves dramatic results
Why does immunotherapy achieve dramatic results in some cancer patients but doesn’t help others? It is an urgent and vexing question for many cancer specialists.
Can Bile Duct Cancer’s follow the Melanoma lead
Patients with metastatic melanoma who are treated with pembrolizumab and achieve a complete response (CR) can maintain those responses for an extended period, even after discontinuation of the therapy, according to a new study.
Bayer enters the immunotherapy race
Bayer joins in . . .Loxo is trying to repeat the trick achieved by Merck & Co (known as MSD outside the US and Canada) when it secured approval for PD1 inhibitor Keytruda (pembrolizumab) for all cancers, regardless of location in the body
Servier Interviews Stage 4 Cholangiocarcinoma Survivor Steve Holmes
Steve Holmes on survival, his brother Graeme's cholangio battle, founding the Cholangiocarcinoma Foundation Australia and Light Australia Green
Leading the Future of Cholangiocarcinoma Care—Because No One Else Will
Landmark Event: Leading experts & patient advocates united for the largest-ever event on cholangiocarcinoma treatment standardisation in Australia, driving innovation & action.
Catie Brown
Malua Bay mum Jill Brown’s mission to educate Australia on rare cancer that killed ‘beautiful’ daughter Catie. Jill Brown tragically lost her “beautiful” daughter Catie Brown in early 2023, after a hard fought six month battle with cholangiocarcinoma, a rare bile duct cancer.
Understanding Bilirubin: Your Body’s Natural Blood Compost
Learn about bilirubin, its role in your body, symptoms like jaundice and itching, and how to track and respond to changes that impact liver and bile health.
TAS-120: Futibatinib in Advanced Cholangiocarcinoma with FGFR2 Fusions
TAS-120 (Futibatinib) offers hope for advanced cholangiocarcinoma with FGFR2 fusions. Explore the groundbreaking FOENIX-CCA4 Phase 2 study results.
Orphan Drug for Intrahepatic Bile Duct Cancer
Discover how PLT012, an innovative anti-CD36 antibody, targets liver cancer's sneaky recruitment stations, starving tumours, dismantling defences, and empowering T-cells to attack.
World-First Pilot Study Explores New Cholangiocarcinoma Treatment
Join a world-first pilot study testing durvalumab and olaparib for advanced cholangiocarcinoma. Now recruiting at eight sites across Australia. Learn more.
Lynette Williams cholangiocarcinoma survivor
Lynette Williams’ journey from diagnosis to survival highlights the impact of knowledge, advocacy, and expert care in beating cholangiocarcinoma.
Immunotherapy and Chemotherapy Combinations for Cholangiocarcinoma
FDA approves Keytruda combo for cholangiocarcinoma, expanding options alongside Durvalumab. Explore immunotherapy breakthroughs and chemo combinations.
Jon’s Five-Year Cholangiocarcinoma Journey
Jon’s journey with cholangiocarcinoma is a testament to resilience and determination. Nearing her five-year milestone, she shares the strength that has kept her fighting.
The Luckiest Unlucky Guy – The Matt Reidy Story
Matt's story shines a light on overcoming cholangiocarcinoma, from diagnosis and treatment to becoming a beacon of hope in the cancer community.
Evaluating the New Cholangiocarcinoma Vaccine Trial: A Patient-Centric Analysis”
An in-depth analysis of a cholangiocarcinoma vaccine trial, designed to empower patients with balanced insights into this experimental treatment.
Fixing Broken IDH1 in Cholangiocarcinoma: How Inhibitors Are Changing the Fight
Discover how blocking broken IDH1 with inhibitors is helping cholangiocarcinoma patients. Cholangiocarcinoma Foundation Australia is helping better equip and empower patients to respond more effectively.
IDH1-Mutated Cholangiocarcinoma: Understanding PARP Inhibitors and Clinical Trials
Explore the latest research and clinical trials involving PARP inhibitors for treating IDH1-mutated intrahepatic cholangiocarcinoma.
Michael Flannery: Life Goes On: My Journey with Cholangiocarcinoma
Michael’s Journey: Overcoming Cholangiocarcinoma with Resilience, creative persistence, Hope, and Action gave him back a normal life
Steve Holmes Patient Survivor: 14000 kilometre Cycling Circumnavigation of Australia
Cycling to Empower patients. Transform survival outcomes. Support our innovative cancer response strategies and make a real difference today.
The Checkpoint Pathway: Ipilimumab and Keytruda immunotherapy combination
Discover how the combination of Ipilimumab and Keytruda removes the brakes and disguises cancer cells use to evade the immune system, offering new hope through immunotherapy.
Understanding BRCA1 and BRCA2 in Cholangiocarcinoma
Discover how BRCA1, BRCA2, and BAP1 genes influence cholangiocarcinoma and why understanding them is crucial for effective treatment.
Bile Gone Bad-Article 3: Understanding Bile Duct Damage and Bile Duct Cancers
Uncover the hidden link between poor bile composition and the alarming rise in bile duct cancer rates.
Meet GEM/CIS/DURVA: A Formidable Trio in the Fight Against Cancer
Discover how GEM/CIS/DURVA works to fight cholangiocarcinoma more effectively
Silent Chronic Inflammation and Rising Cholangiocarcinoma, Especially in Younger Patients
Investigate the role of poor bile composition in the increasing rates of bile duct, liver, and pancreatic cancers.
Bile Gone Bad: The Rising Incidence of Bile Duct Cancer – The Hidden Dangers within Bile Composition
Is your diet turning your bile toxic? Learn about the hidden cancer risks and how to protect your health.
Unlocking the Power of Immunotherapy and Gem/Cis: A Strategic Battle Plan for Fighting Cholangiocarcinoma
Discover the powerful synergy of immunotherapy and Gem/Cis in fighting cholangiocarcinoma and empowering patient survival. Discover the powerful synergy of immunotherapy and Gem/Cis in fighting cholangiocarcinoma and empowering patient survival.
Meet Olaparib: A Key Player in the Fight Against Cancer
Discover how Olaparib, a breakthrough PARP inhibitor, enhances cancer treatment for patients with BRCA mutations. Learn more about its benefits and uses.
Defeating Biliary Tract Cancer with ARTEMIDE-Biliary01: A New Hope
Uncover how ARTEMIDE-Biliary01 could revolutionize biliary tract cancer treatment with innovative adjuvant therapy.
AMG193 Trial targets MTAP Loss
Just Imagine a big school where every student (cell) has a special recycling bin called MTAP but for some reason they disappear or the lid wont open the rubbish piles up and...
Brenda’s Testimonial
It's been an absolute whirlwind as she was dying in my arms 2 weeks ago and the Drs didn't want to treat her - now we have this option, thankyou!
James Hastings Testimonial
Hope you guys made it home and sound, just read the patient journal cover to cover, (on my flight to UCL for next round of Nivo) it's incredible,.the detail, the path it forges, the ideas and inspiration. Truly amazing and exactly what is needed to navigate CCA, Brilliant James Hastings - Ireland
AstraZeneca’s Imfinzi breaks decade Long Drought in Cholangiocarcinoma
IMFINZI® will serve as a first-line treatment for locally advanced or metastatic cholangiocarcinoma in combination with chemotherapy (Gem/Cis).
Transforming Cancer Perceptions: The Power of Objectivity
Putting Cancer in Its Rightful Place — A Journey Toward Empowered Patienthood
Exploring HIPEC Surgery: A Potential Ally in Abdominal Cancer Battles
Discover HIPEC Surgery, an innovative treatment for abdominal cancers. Learn how it works, its benefits, and who can benefit from it.
Clarifying: What is the Checkpoint Pathway?
It is the Successful Handshake that that Occurs between 'PD-1' - the T-Cells Checkpoint Police Officer and 'PD-L1' The Healthy Cells Good Citizen Pass.
The Basics difference between Gem/Cis with Durvalumab vs. Keytruda
Explore the differences in cancer treatments using Gem/Cis with Durvalumab versus Keytruda, focusing on innovative immunotherapy strategies for patient empowerment.
Merck’s Keytruda: A New Hope in Biliary Tract Cancer
Merck's Keytruda gains FDA approval for biliary tract cancer, promising extended survival, rivaling AstraZeneca’s Imfinzi.
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
PBAC endorses IMFINZI (durvalumab) for advanced biliary tract cancer in Australia. First new treatment in 10+ years, boosting survival rates.
Testimonials
CCF Australia is a professional 'Patient-Centric' and 'Patient-Led' Organisation, [...]
Steven West: Cholangio Survivor
The opportunity to help other newly diagnosed patients help themselves, to understand in a manner that they can mount a robust and effective response is the reward
Lynette Williams: Cholangiocarcinoma Survivor
In order to successfully fight this disease we need to be armed with as much information as possible.
Lisa Salem-Craine: Cholangio Survivor
I met Steve and Claire Holmes many years ago and connected with them because like Steve, I am a cholangiocarcinoma survivor.
Lisa Craine
Beating Cholangiocarcinoma, a bile duct cancer. After several resections and lot of determined research Lisa prevailed
Melinda Bachini
Surviving Cholangiocarcinoma a bile duct cancer is a significant challenge within the cancer world. Melinda Bachini took it on with an amazing supporter community underpinned by willingness and persistence.
Second Opinions Save lives
Second Opinions are a critical factor in surviving Cholangiocarcinoma a bile duct cancer, it an mean the difference between life and death
Andrea Sheardown
Taking on challenges creates a positive environment and positive is what works for Andrea
Intrahepatic Cholangiocarcinoma – Diagnosis and Treatment
Fralin Biomedical Research Institute Timothy Pawlik, M.D., Ph.D. dives deep into discovering and treating intrahepatic cholangiocarcinoma
World Cholangiocarcinoma Day
Contribution and Sharing are powerful human elements in the cancer cure equation - this is my contribution.
Treat the Immune not the Cancer
A breakthrough by Dr Jim Allison Nobel Prize winner - we look into the Ipi /Nivo treatment, a two pronged attack on reactivating the T-Cell
What are Biomarkers
Biomarkers may be used to better understand some of the characteristics of your cancer. Getting tested for biomarkers helps your doctor decide what options are right for you.
PD-1 / PD-L1 is the Checkpoint Pathway
Learn how simple the PD-1 / PD-L1 Pathway is to understand - 4 short videos from easy to technical
A future look into Immuno-Oncology
what a line up! 2018 Nobel Prize winner James P. Allison, Philip D. Greenberg, M.D and Robert H. Vonderheide, Ph.D., and a fireside chat featured insights and opinions from Bristol-Myers Squibb's Vice President, Head of U.S. Oncology
Blood Biopsies increasing MSI-high detection
A barrier to improved outcomes for many patients is the awareness and testing of MSI status
Ariella Chivil, Cancer Patient success – immunotherapy
Ariella Chivil, an Immunotherapy Advocate, shares her story of self-advocacy and resilience as a young survivor of Hodgkin lymphoma at the 2019 CRI Immunotherapy Summit in Boston.
Cholangiocarcinoma beyond the Blockade
Breakthroughs, Options and Opportunities opening up beyond the Check point inhibitor - beyond PD-1 and the T Cell
Mandy Wallace – NED Cholangiocarcinoma Patient
NED 7.5 years - I woke up on the morning of my 39th birthday with severe pain in my upper abdomen. By lunchtime I had to canceled my birthday party and went to hospital Emergency Department instead. The hospital concluded that I had gallbladder issues, so an ultrasound was scheduled and was sent home with given painkillers to await an ultrasound.
Cholangiocarcinoma and FGFR2
FGF and FGFR2 is a signalling pathway - Fibroblast growth factor signalling uses a fibroblast growth factor receptor (FGFR2) ligand during cell cycle and cell division. The ligand embeds itself into the cell membrane to recieve and deliver growth factors into the cell.
Gem/Cis gets nab-paclitaxel
So, knowing I had no clinical trials for them motivated me to try to write one and think of one that would be something anyone sitting in my clinical could be considered for because that’s what they need.
Scanxiety a new challenge and a special thank you
A Contradiction - It has been what seems like a very long, difficult and unusual battle / journey and with contradictions aside has passed in the blink of an eye.
CCA Patient Toolkit
Step-by-step guide & toolkit for bile-duct cancer patients and caregivers, a road map that shines a light on the best pathway ahead
Cholangiocarcinoma Network
Cholangiocarcinoma Australasia Support Network World Wide - Reaching for a Cure
Immuno 101
An extract collection of material and articles that relate to Cholangiocarcinoma
Susan Randolph Braden’s Can Sir Production
March 2019 has come roaring in like a lion, and like a Mama lioness, I have been aggressively battling my cancer predator this month.
CCA Introduction pack
Cancer breakthrough -The Globally connected patient and caregiver knowledge, experiences and wisdoms - a collective the equips and empowers
Steve and Claire at the 2019 Cholangiocarcinoma Foundation Annual Conference
Steve and Claire at the 2019 Cholangiocarcinoma Foundation Annual Conference [...]
Genomic Testing – Know your mutations
Molecular Testing Know your Mutations , Information is powerful it improves outcomes
MSI Predictive Biomarkers GI
Experts John L. Marshall, MD, and Alan Venook, MD, comment on the evolution of testing for microsatellite instability (MSI) and tumor mutation burden (TMB
Maria
Maria Shearer shares her story with Cholangiocarcinoma and founding The Cholangiocarcinoma Awareness Facebook Group Community. A Caregivers Story with a twist. Maria Shearer has endured and she has made a difference, she stepped out and up to help others.
Dr Charles Drake explains about Exhausted T Cells
Dr Charles Drake explains about Exhausted T Cells in immunotherapies [...]
Michael Lax sought a second opinion
Michael Lax sought a second opinion on Cholangiocarcinoma at UCSF [...]
Melinda Bachini’s Cholangiocarcinoma Patient Perspective
Melinda Bachini's Cholangiocarcinoma Patient Perspective on Adoptive Cell Therapy,
Treatment options improving for Cholangiocarcinoma
Treatment options improving for Cholangiocarcinoma with Kate Kelly encouraging clinicians to perform tumor profiling
The Immuno sliver bullet; is Immunotherapy a “silver bullet” or is it hype?
The Immuno sliver bullet; is Immunotherapy a “silver bullet” or [...]
Bile Ducts made easy – bile ducts, liver, stomach, pancreas, duodenum
Bile Ducts made easy - An easy to follow video on the relationship between the bile ducts, liver, stomach, pancreas, duodenum and more such as Ampular, Hepatic Artery . . .
Chemotherapy and Cholangiocarcinoma
Chemotherapy and Cholangiocarcinoma - The future direction of Chemotherapy in [...]
As a Cholangiocarcinoma patient living in Australia
As a Cholangiocarcinoma patient living [...]
Cholangio Immuno Warrior strikes another blow on “Cholangio the Beast”
Hi everybody! I think its time for an update because I feel so many of you need some hope. More than ever. I have noticed there are fewer positive news in the last months.
Cholangiocarcinoma – Keytruda as a first line treatment option ?
Cholangiocarcinoma - Keytruda as a first line treatment option ? [...]
Treatment of Intrahepatic Cholangiocarcinoma: A Disease on the Rise
Cholangiocarcinoma - Treatment of Intrahepatic Cholangiocarcinoma: A Disease on the [...]
Surgery for Bile Duct Cancer
Surgery for Bile Duct Cancer, There are 2 general types [...]
Investigating the Biliary RFA Procedure
Investigating the Biliary RFA Procedure for Extrahepatic Cholangiocarinoma Information improves [...]
Sarah Bennett & Linda Fleischer
Cholangiocarcinoma Warrior founder Sarah Bennett and her mother Linda Fleischer [...]
Cholangiocarcinoma – About and Options by Mayo Clinic
Cholangiocarcinoma - Sumera H. Rizvi, MBBS. Gastroenterology fellow at Mayo [...]
Katie Barker, University of Utah 2018, Cholangiocarcinoma and Nutrition
Cholangiocarcinoma and Nutrition and Gastro Intestinal Cancers information that needs [...]
Cholangiocarcinoma Treatment lmproving
THE INCIDENCE of cholangiocarcinoma is rising, and effective therapies are [...]
Adrienne Skinner Cholangiocarcinoma and Keytruda
Adrienne Skinner: Living Life to [...]
Keytruda works on Cholangiocarcinoma Patient
Keytruda works on Cholangiocarcinoma Patient. Adrienne Skinner of Larchmont, [...]
Keytruda may be a miracle cancer drug
Keytruda may be a miracle cancer drug but big questions are being asked about affordability to the people who need it most
Vyriad Expands Phase 1 Trial to Test Voyager-V1
Vyriad is expanding its ongoing Phase 1 clinical trial [...]
Rare Cancers Australia 33 Million Win
The Turnbull Government will provide $33 million to our world [...]
Cycling in the Chemo
Cancer hospital getting chemo patients on bikes to [...]
Bile Duct Cancer – How it develops and how to prevent it
Information improves our Outcomes What do you think about [...]
Capecitabine Improves Survival of Patients with Rare Cancer by Almost a Quarter
Information improves our Outcomes What do you think about [...]
CC with Andrew Clacher
“Having a cancer and no one knowing what it is, or what your fate’s going to be, or even if you’re going to be here in the next two years – it really makes you think about your mortality.”
Elishka’s Story
Choliangiocarcinoma: miss Cholangio was diagnosed in Oct 2015, after I had symptoms of menopause, it was already 7cm x 8cm in the liver, and wrapped around all three major blood vessels, so no surgery for me
Immunotherapy achieves dramatic results
Why does immunotherapy achieve dramatic results in some cancer patients but doesn’t help others? It is an urgent and vexing question for many cancer specialists.
Can Bile Duct Cancer’s follow the Melanoma lead
Patients with metastatic melanoma who are treated with pembrolizumab and achieve a complete response (CR) can maintain those responses for an extended period, even after discontinuation of the therapy, according to a new study.
Bayer enters the immunotherapy race
Bayer joins in . . .Loxo is trying to repeat the trick achieved by Merck & Co (known as MSD outside the US and Canada) when it secured approval for PD1 inhibitor Keytruda (pembrolizumab) for all cancers, regardless of location in the body
